AUSTIN, Texas - TelAve -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is delivering another significant scientific development, with its November 5 announcement presenting new patient-derived research suggesting that its lead investigational gene therapy, REQORSA® (quaratusugene ozeplasmid), activates cellular repair and maintenance programs associated with resilience to aging-related stress.

This latest announcement adds an exciting dimension to Genprex's growing scientific story. Researchers analyzed blood samples from patients receiving REQORSA in clinical trials and identified changes in gene-expression patterns involving mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

The findings are particularly interesting because they move beyond laboratory models and provide additional insight into how TUSC2, the tumor-suppressor gene delivered by REQORSA, behaves in humans following treatment.

For investors, this represents another important research milestone as Genprex continues developing its gene therapy platform for lung cancer while exploring the broader biological functions of TUSC2.

Importantly, this research also builds on the company's collaboration with Meharry Medical College and adds scientific depth to a development strategy that already includes its strategic Roche Diagnostics relationship, emerging biomarker research and a separate diabetes gene therapy program.

November 5 Announcement: REQORSA Demonstrates Promising Cellular Repair and Maintenance Activity in Patient Analysis

The latest announcement centers on a translational analysis of whole-blood samples from 11 lung cancer patients enrolled in two clinical trials evaluating REQORSA.

Researchers collected samples before treatment and at five and 24 hours following intravenous administration. By examining changes in gene expression over these intervals, investigators were able to study both the immediate response to treatment and the subsequent biological changes.

One of the most interesting findings was a two-stage response.

At five hours, researchers observed activity involving innate immune, interferon, nucleic-acid-sensing and chemokine pathways, consistent with an early response to the treatment delivery system.

By 24 hours, the researchers identified a shift toward increased expression of genes involved in several important cellular processes:

• Mitochondrial adaptation: Changes involving the cellular structures responsible for energy production and metabolic activity.
• Autophagy and lysosomal function: Biological processes involved in breaking down and recycling damaged or unnecessary cellular components.
• Protein quality control: Increased activity involving the endoplasmic reticulum and its role in properly folding and maintaining proteins.
• Cellular maintenance: A broader gene-expression pattern associated with repair and quality-control functions.

Researchers also observed recovery in oxidative phosphorylation gene expression following an initial reduction, while certain growth-related signaling pathways showed reduced activity.

More on TelAve News

• PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
• KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
• Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
• New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
• Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs

The significance is that the patient-derived findings provide additional insight into the biological activity associated with TUSC2 expression following REQORSA administration.

Genprex believes this research strengthens the scientific foundation of its REQORSA platform and provides additional opportunities to investigate the broader role of TUSC2 in cellular resilience.

The findings were presented at the Gerontological Society of America's 2026 Annual Scientific Meeting, taking place November 4–7 in National Harbor, Maryland.

Roche Diagnostics Collaboration: Advancing a More Personalized Approach to Lung Cancer

Another major component of Genprex's developing story is its collaboration with Roche Diagnostics.

Announced August 3, the collaboration focuses on validating biomarker assays that could help identify non-small cell lung cancer patients more likely to respond to REQORSA.

The research centers on two important biomarkers: TROP2 and PTEN.

TROP2 is particularly interesting because Genprex has reported findings associating its expression with sensitivity to REQORSA treatment. PTEN is another tumor-suppressor protein being investigated for its potential relationship with treatment response.

Roche brings extensive diagnostic expertise to this initiative, while Genprex contributes its developing gene therapy platform and clinical research.

The collaboration is intended to establish a more refined approach to biomarker testing, potentially helping researchers improve patient selection in future clinical studies.

Genprex anticipated completing the validation studies around the end of 2026, with potential integration into its NSCLC clinical program following successful validation.

This partnership represents an important strategic relationship as precision medicine becomes an increasingly important component of modern cancer treatment.

New TROP2 Research Adds Another Important REQORSA Milestone

On November 4, Genprex announced additional research identifying TROP2 expression as a potential predictive biomarker for response to REQORSA.

Researchers found that low TROP2 expression was consistently associated with primary resistance across multiple preclinical non-small cell lung cancer models.

Importantly, analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial provided supporting evidence for the relationship.

The findings also suggested that manipulating TROP2 expression could influence treatment sensitivity, creating another area for scientific investigation.

The research is scheduled for presentation November 18–20 at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

For Genprex, the combination of TROP2 research and the Roche Diagnostics collaboration could become an important part of its precision-oncology strategy.

REQORSA: Building an Innovative Lung Cancer Treatment Platform

At the center of Genprex's oncology development program is REQORSA, designed to deliver the TUSC2 tumor-suppressor gene into cancer cells through the company's proprietary ONCOPREX Delivery System.

TUSC2 is frequently reduced or absent in several forms of lung cancer. The objective of REQORSA is to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression.

Genprex is advancing two important clinical development initiatives.

More on TelAve News

• Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
• IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
• FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
• Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
• Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families

Acclaim-1 evaluates REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced non-small cell lung cancer carrying specific EGFR mutations.

Acclaim-3 evaluates REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both lung cancer programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

The company's growing biomarker research could provide additional direction as these programs continue developing.

Diabetes Gene Therapy Provides Another Potential Growth Opportunity

Genprex's ambitions extend beyond oncology through its separate gene therapy program targeting Type 1 and Type 2 diabetes.

The program uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical research has produced encouraging findings involving glucose control and insulin-related measures in animal models.

On August 18, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This represents another important development as the company works toward preparing the program for future clinical studies.

The diabetes program provides Genprex with an additional therapeutic area and expands the potential reach of its gene therapy technology.

Upcoming Catalysts: Important Developments for GNPX Investors

Genprex has several important milestones approaching:

• November 18–20: Presentation of new TROP2 biomarker research in Barcelona.
• Late 2026: Anticipated completion of Roche Diagnostics biomarker assay validation studies.
• Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
• Additional TUSC2 research and scientific collaboration developments.
• Continued manufacturing scale-up and development of the diabetes gene therapy program.

Genprex Is Expanding Its Scientific Story

$GNPX brings together several compelling areas of biotechnology innovation, including precision lung cancer treatment, gene therapy, biomarker-guided patient selection, cellular biology and diabetes research.

Today's November 5 announcement is particularly noteworthy because it provides additional patient-derived evidence of biological changes associated with REQORSA administration. The observed activity involving mitochondrial adaptation, autophagy and protein quality control adds another layer to researchers' understanding of TUSC2 and its potential biological importance.

Combined with the Roche Diagnostics collaboration and the latest TROP2 findings, Genprex is continuing to build a broader scientific foundation around its lead oncology candidate.

The company's upcoming international research presentation, anticipated biomarker validation milestones and continuing clinical development provide several developments for investors to follow.

For investors watching emerging biotechnology companies, Genprex offers an increasingly interesting story built around innovative gene therapy research, strategic collaboration and multiple therapeutic development opportunities. With new patient-derived findings adding to the REQORSA research foundation, the company's next chapter will be particularly interesting to watch.

For more information on $GNPX visit: www.genprex.com      and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website